Stromal PDGFRβ expression in prostate tumors and non- malignant prostate tissue predicts prostate cancer survival

PLoS ONE

Volumn 5, Issue 5, 2010, Pages

  Hägglöf, Christina ^a   Hammarsten, Peter ^b   Josefsson, Andreas ^b   Stattin, Pär ^b   Paulsson, Janna ^a   Bergh, Anders ^b   Östman, Arne ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UMEÅ UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; ACTIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE ASSOCIATION; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PROGNOSIS; PROSTATE CANCER; PROTEIN EXPRESSION; TUMOR VASCULARIZATION; TUMOR VOLUME; BLOOD VESSEL; METABOLISM; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; PROSTATE; PROSTATE TUMOR; REGRESSION ANALYSIS; STAINING; STROMA CELL; SURVIVAL;

ACTINS; BLOOD VESSELS; HUMANS; MALE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSTATE; PROSTATIC NEOPLASMS; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; REGRESSION ANALYSIS; STAINING AND LABELING; STROMAL CELLS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 77956281456     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0010747     Document Type: Article

References (28)

1. Yanagisawa N, Li R, Rowley D, Liu H, Kadmon D, et al. (2007) Stromogenic prostatic carcinoma pattern (carcinomas with reactive stromal grade 3) in needle biopsies predicts biochemical recurrence-free survival in patients after radical prostatectomy. Hum Pathol 38: 1611-1620.
2. Wikstrom P, Marusic J, Stattin P, Bergh A (2009) Low stroma androgen receptor level in normal and tumor prostate tissue is related to poor outcome in prostate cancer patients. Prostate 69: 799-809.
3. Fleischmann A, Schlomm T, Kollermann J, Sekulic N, Huland H, et al. (2009) Immunological microenvironment in prostate cancer: high mast cell densities are associated with favorable tumor characteristics and good prognosis. Prostate 69: 976-981.
4. Karja V, Aaltomaa S, Lipponen P, Isotalo T, Talja M, et al. (2005) Tumourinfiltrating lymphocytes: A prognostic factor of PSA-free survival in patients with local prostate carcinoma treated by radical prostatectomy. Anticancer Res 25: 4435-4438.
5. Lissbrant IF, Lissbrant E, Damber JE, Bergh A (2001) Blood vessels are regulators of growth, diagnostic markers and therapeutic targets in prostate cancer. Scand J Urol Nephrol 35: 437-452.
6. Tammi RH, Kultti A, Kosma VM, Pirinen R, Auvinen P, et al. (2008) Hyaluronan in human tumors: pathobiological and prognostic messages from cell-associated and stromal hyaluronan. Semin Cancer Biol 18: 288-295.
7. Lissbrant IF, Stattin P, Wikstrom P, Damber JE, Egevad L, et al. (2000) Tumor associated macrophages in human prostate cancer: relation to clinicopathological variables and survival. Int J Oncol 17: 445-451.
8. Halin S, Hammarsten P, Wikstrom P, Bergh A (2007) Androgen-insensitive prostate cancer cells transiently respond to castration treatment when growing in an androgen-dependent prostate environment. Prostate 67: 370-377.
9. Nonn L, Ananthanarayanan V, Gann PH (2009) Evidence for field cancerization of the prostate. Prostate 69: 1470-1479.
10. Hammarsten P, Karalija A, Josefsson A, Rudolfsson SH, Wikstrom P, et al. (2010) Low levels of phosphorylated epidermal growth factor receptor in nonmalignant and malignant prostate tissue predict favorable outcome in prostate cancer patients. Clin Cancer Res 16: 1245-1255.
11. Heldin CH, Westermark B (1999) Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 79: 1283-1316.
12. Andrae J, Gallini R, Betsholtz C (2008) Role of platelet-derived growth factors in physiology and medicine. Genes Dev 22: 1276-1312.
13. Ostman A, Heldin CH (2007) PDGF receptors as targets in tumor treatment. Adv Cancer Res 97: 247-274.
14. Skobe M, Fusenig NE (1998) Tumorigenic conversion of immortal human keratinocytes through stromal cell activation. Proc Natl Acad Sci U S A 95: 1050-1055.
15. Forsberg K, Valyi-Nagy I, Heldin CH, Herlyn M, Westermark B (1993) Plateletderived growth factor (PDGF) in oncogenesis: development of a vascular connective tissue stroma in xenotransplanted human melanoma producing PDGF-BB. Proc Natl Acad Sci U S A 90: 393-397.
16. Pietras K, Ostman A, Sjoquist M, Buchdunger E, Reed RK, et al. (2001) Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res 61: 2929-2934.
17. Pietras K, Rubin K, Sjoblom T, Buchdunger E, Sjoquist M, et al. (2002) Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res 62: 5476-5484.
18. Pietras K, Pahler J, Bergers G, Hanahan D (2008) Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting. PLoS Med 5: e19.
19. Kitadai Y, Sasaki T, Kuwai T, Nakamura T, Bucana CD, et al. (2006) Targeting the expression of platelet-derived growth factor receptor by reactive stroma inhibits growth and metastasis of human colon carcinoma. Am J Pathol 169: 2054-2065.
20. Johansson A, Jones J, Pietras K, Kilter S, Skytt A, et al. (2007) A stroma targeted therapy enhances castration effects in a transplantable rat prostate cancer model. Prostate 67: 1664-1676.
21. Paulsson J, Sjoblom T, Micke P, Ponten F, Landberg G, et al. (2009) Prognostic significance of stromal platelet-derived growth factor beta-receptor expression in human breast cancer. Am J Pathol 175: 334-341.
22. Ayala G, Thompson T, Yang G, Frolov A, Li R, et al. (2004) High levels of phosphorylated form of Akt-1 in prostate cancer and non-neoplastic prostate tissues are strong predictors of biochemical recurrence. Clin Cancer Res 10: 6572-6578.
23. Sugimoto H, Mundel TM, Kieran MW, Kalluri R (2006) Identification of fibroblast heterogeneity in the tumor microenvironment. Cancer Biol Ther 5: 1640-1646.
24. Orimo A, Weinberg RA (2007) Heterogeneity of stromal fibroblasts in tumors. Cancer Biol Ther 6: 618-619.
25. Mathew P, Pisters LL, Wood CG, Papadopoulos JN, Williams DL, et al. (2009) Neoadjuvant platelet derived growth factor receptor inhibitor therapy combined with docetaxel and androgen ablation for high risk localized prostate cancer. J Urol 181: 81-87; discussion 87.
26. Mathew P, Thall PF, Bucana CD, Oh WK, Morris MJ, et al. (2007) Plateletderived growth factor receptor inhibition and chemotherapy for castrationresistant prostate cancer with bone metastases. Clin Cancer Res 13: 5816-5824.
27. Josefsson A, Wikstrom P, Granfors T, Egevad L, Karlberg L, et al. (2005) Tumor size, vascular density and proliferation as prognostic markers in GS 6 and GS 7 prostate tumors in patients with long follow-up and non-curative treatment. Eur Urol 48: 577-583.
28. Nupponen NN, Paulsson J, Jeibmann A, Wrede B, Tanner M, et al. (2008) Platelet-derived growth factor receptor expression and amplification in choroid plexus carcinomas. Mod Pathol 21: 265-270.